Deepinder Goyal’s Temple wearable will open Batch 01 pre-orders on November 1, 2026, featuring BrainFlow technology, six colour options and early 2027 deliveries.
Temple, a new wearable device designed to monitor physiological signals from the head, is set to open its first pre-order window on November 1, 2026. Deepinder Goyal confirmed the development through a post on X, announcing the launch of Temple Batch 01.
The device is designed to be worn near the temple area of the head and focuses on tracking signals associated with brain activity, including changes in blood flow.
However, customers placing orders should expect a waiting period. Each unit will be assembled by hand, with shipping expected within three months of purchase. Based on the announced timeline, the earliest deliveries are anticipated in early 2027.
The company has not officially disclosed the price of the Temple wearable. However, market speculation suggests that the device could cost approximately ₹1 lakh. This figure remains unconfirmed and should not be treated as the final launch price.
The first edition is expected to be available in six colour options, giving buyers a choice of finishes.
Goyal has also indicated that customers who registered for the early-access waitlist will receive priority when pre-orders begin.
Temple is designed differently from conventional smartwatches and fitness trackers. Instead of primarily monitoring physical activity, heart rate or sleep patterns, it aims to measure physiological signals linked to the brain.
The device sits on the side of the head and can be worn alongside regular spectacles.
It uses photoplethysmography (PPG), a technology commonly found in smartwatches and other health-monitoring wearables. PPG uses light-based measurements to detect changes associated with blood circulation.
One of Temple's key features is BrainFlow, which is designed to track changes in blood flow to the brain. The objective is to provide information about physiological variations that may offer insights into the body's condition.
However, the practical value of these measurements still needs to be established through further research and testing outside controlled laboratory environments.
Goyal recently shared findings from Temple's second validation study, which involved 60 participants.
According to the reported results, BrainFlow measurements showed a correlation ranging from 0.84 to 0.91 with changes in brain blood volume measured using time-domain near-infrared spectroscopy (NIRS).
The researchers examined the measurements under three different conditions. The strongest correlation was observed during a head-down tilt test.
These findings offer an early indication that the device may be capable of tracking changes associated with cerebral blood flow. However, the study is currently available as a preprint and is awaiting peer review.
The results should therefore be viewed as preliminary evidence rather than proof of clinical accuracy. Further independent research will be necessary to establish the device's reliability in everyday situations.
Temple should not currently be considered a medical diagnostic device or a replacement for established clinical monitoring tools.
Goyal has also discussed possible future uses of Temple beyond personal health monitoring.
Potential applications could include assessing whether pilots are physiologically fit to fly and helping identify suitable candidates for certain Air Force missions.
These possibilities remain exploratory. Their implementation would require additional scientific validation, practical testing and relevant regulatory approvals.
For now, such applications should be viewed as long-term possibilities rather than confirmed features of the first-generation device.
One of the more ambitious ideas associated with Temple is the possibility of translating thoughts into written text. Goyal has suggested that this capability could be considered in the device's third or fourth generation, potentially placing it several years away.
There is currently no confirmed development schedule or technical roadmap for this feature. It remains a longer-term research ambition and is not part of the functionality promised for the initial release.
The November 1 pre-order launch is the immediate milestone for people interested in Temple. Early-access waitlist members are expected to receive priority, while each device will be individually assembled and shipped within three months of purchase.
With official pricing and complete specifications still awaited, potential buyers should distinguish confirmed information from estimates and future possibilities.
The device's BrainFlow technology and early research findings are attracting attention, but independent validation will be important in determining its usefulness for everyday health monitoring.